01 / TITRATION
Adeno-associated virus titration
Quantify genome copies by qPCR or ddPCR and, where relevant, infectious titer by cell-based assay with units and methods clearly reported.
AAV Quality Control Resource
AAV Quality Control: Titer, Potency, Purity, and Safety Testing
Reliable AAV quality control requires more than measuring genome titer. A fit-for-purpose panel combines genome and functional titer, capsid occupancy, genome integrity, protein and residual impurity testing, safety attributes, and stability to determine whether a lot is consistent, active, and suitable for its intended use. These orthogonal measurements support informed decisions across AAV titer testing, viral vector purity analysis, and AAV purification and characterization.
01 Genome titer Both qPCR and ddPCR assays reliably report viral genome copies per mL (vg/mL).
02 Functional titer Specify the cell-based endpoints and units; TU/mL and IU/mL require assay context.
03 Purity & empty capsids VP ratio, empty/full/partial particles, and residual impurities.
04 Integrity & safety Genome completeness, endotoxin, sterility, and mycoplasma.
Direct Answer
Why high titer is not enough
Most researchers check titer first when they receive an AAV lot, but titer only answers one question. Two lots with nearly identical vg/mL can differ markedly in expression because the real difference lies in particle quality, empty-capsid ratio, and genome integrity—none of which titer captures.
Quality control exists to surface these risks before they reach an experiment. Its value is not simply a completed report, but early identification of anything that could compromise transduction, expression, or reproducibility.
The key principle: evaluate titer, functional activity, purity, empty-capsid ratio, genome integrity, and residuals together, because each answers a different question about the same lot.
Titer
How many genomes are present?
Genome titer quantifies vg/mL but does not establish that the virus can actually transduce and express the transgene.
Functional activity
Can those particles transduce?
Cell-based assays measure defined infection or expression endpoints. Therapeutic potency requires a readout related to the intended biological effect.
Purity
What else is in the tube?
Particle composition and impurities can affect product interpretation and biological responses; their effects depend on the product and experimental context.
Safety
Is the lot free of contamination?
Endotoxin, sterility, and mycoplasma testing protect the experiment from hidden variables that mimic poor vector performance.
QC Modules
The six modules of AAV quality control
AAV QC is built from six connected modules. Together they support a more informative assessment, but do not guarantee performance in every biological model.
01 / Titer
Genome titer detection
Titer is the most fundamental AAV QC item, quantifying the number of viral genomes in a sample. Results are typically expressed as vg/mL or GC/mL (genome copies per mL).
- qPCR is widely used, with a short turnaround suited to routine quantification.
- ddPCR uses absolute quantification and usually offers better reproducibility and precision.
- Titer alone has limits: it reflects genome number, not whether the virus can truly transduce.
Two lots with similar titer can differ in expression—the cause lies in particle quality, empty-capsid ratio, and genome integrity. See AAV titration and titer of viral vector.
02 / Potency
Functional titer detection
Functional, transduction, or infectious assays asks not "how much virus" but "does this virus transduce and express the target gene." Common readouts include:
- Cell transduction experiments and reporter-gene expression.
- Target-protein expression analysis.
- qPCR/ddPCR combined with transduced-cell analysis.
- TCID50 or equivalent infectivity assays.
Report TU/mL, IU/mL, or other units only as defined by the assay. An infectivity endpoint, transgene-expression endpoint, and biological-function endpoint address different questions.
03 / Purity
Viral purity detection
Production yields more than virus: host-cell protein, nucleic-acid residues, degradation products, and process-related impurities can all remain. SDS-PAGE is the common method for observing capsid composition.
- AAV capsids contain VP1, VP2, and VP3 in a classical ~1:1:10 ratio (serotype- and process-dependent).
- Check for abnormal bands, protein degradation, and contaminating protein; silver staining adds sensitivity for dilute samples.
- SEC-based methods can support aggregation assessment, while CE-SDS provides a denaturing protein profile. Their endpoints should not be treated as interchangeable.
Purity problems may stay hidden at first but surface in animal or long-term studies as inflammation, elevated background, and reduced reproducibility. See purity of viral vector.
04 / Empty Capsids
Empty-capsid ratio detection
AAV packaging is not uniform. A final sample usually contains full capsids, empty capsids (intact shells without a genome), and partial capsids carrying incomplete genomes.
- Empty particles lack a packaged transgene. Partial particles carry heterogeneous DNA and their activity depends on the retained sequence and the assay; occupancy alone does not establish function.
- AUC (analytical ultracentrifugation) resolves empty, full, and partial particles with high resolution.
- TEM provides morphology and method-dependent particle-content estimates. SEC-based approaches can support aggregation or compositional assessment, but routine SEC alone does not universally resolve empty, full, and partial capsids.
An increased empty fraction changes particle composition. Its consequences depend on dose normalization, formulation, and biological context; assess occupancy alongside genome integrity and relevant activity.
05 / Integrity
Genome integrity detection
The conventional single-stranded AAV genome capacity is approximately 4.7 kb, including the ITRs; self-complementary designs have a smaller usable capacity. Designs near this limit, or containing repeats, high-GC regions, or complex regulatory elements, are prone to abnormal packaging.
- Common problems include truncated packaging, deletions, recombination, and abnormal fragments.
- Agarose or alkaline agarose gels and Southern blot are classic approaches.
- Multi-site qPCR/ddPCR compares copy numbers across the vector to infer truncation; NGS or long-read sequencing adds detail on sequence integrity, ITR stability, and heterogeneity.
Many weak or unstable expression outcomes trace back to genome integrity rather than to the capsid itself.
06 / Safety
Residual impurities and safety testing
Because AAV is usually produced in cells such as HEK293, the final lot may retain host DNA, packaging-related plasmid DNA, and host-cell protein (HCP).
- Host DNA and HCP are measured by qPCR or HCP ELISA; high residuals indicate the removal or purification step still needs optimization.
- Endotoxin, often from bacterial contamination or plasmid preparation, is detected by the LAL assay and can disturb animal results even at low levels.
- Sterility and mycoplasma testing must not be skipped—mycoplasma is hidden but clearly affects cell state, transcription, and protein expression.
Many "poor vector" cases are ultimately traced to contamination rather than to the AAV itself. See safety of viral vector.
Read Conflicting QC Results Together
Complementary assays are useful because they examine different attributes. Build the testing plan around the unresolved question rather than treating one favorable result as an overall quality label.
| Result pattern | Complementary evidence | Interpretation to avoid |
|---|---|---|
| High genome titer; weak expression | Relevant cell-based activity, genome integrity, and model controls. | Assuming that measured genome copies are all functional. |
| Clear VP bands; unknown occupancy | A qualified particle-content method. | Treating a protein-purity profile as an empty/full measurement. |
| High occupied-particle fraction; uncertain DNA | Size, sequence, or linkage information for packaged DNA. | Equating DNA content with a sequence-correct, intact payload. |
| Different titers across laboratories | Aligned sample preparation, target regions, reference controls, units, and method performance. | Concluding that the lot changed before evaluating analytical differences. |
Genome quantification and particle-content methods are complementary rather than interchangeable.[1][2][3] Use viral vector analysis to discuss the question each result should resolve.
In This Series
AAV quality control deep dives
Explore focused guides on AAV safety, immunogenicity, capsid analysis, and stability to build a complete QC picture.
Key Considerations for Viral Safety Control of AAV Vectors
The safety assays and risk-based thinking needed to evaluate specified viral-safety questions within the scope and detection limits of the chosen methods.
Read the guideIs rAAV Vector Safe?
An evidence-based look at the safety profile of recombinant AAV, including the residual risks and how QC mitigates them.
Read the guideAAV Immunogenicity Analysis and Detection Methods
How pre-existing immunity and capsid- or transgene-driven responses are measured to characterize defined immune-response questions without claiming universal prediction of clinical outcomes.
Read the guideSDS-PAGE vs. Western Blot for AAV QC
When to use gel-based purity analysis versus antibody-based detection for protein composition and antibody-dependent detection; packaged transgene identity requires appropriate nucleic-acid assessment.
Read the guideAAV Full, Empty, and Partial Capsid Analysis
Quantifying full, empty, and partially packaged particles and how particle content complements genome integrity and biological-activity measurements.
Read the guideAAV Freeze-Thaw Stability
How repeated freeze-thaw cycles affect titer and aggregation, and how to handle aliquots to protect vector quality.
Read the guideTesting Strategy
Matching QC depth to intended use
The required QC depth scales with the risk and regulatory status of the application. Research lots, in vivo studies, and clinical-grade material each justify a different testing scope.
Research-grade lots
Define a fit-for-purpose panel: evaluate identity, quantity, relevant activity, purity, and contamination questions for the model. A small set of tests is not sufficient for every cell or animal study.
Decision supported: AAV titration and purity detection.
Preclinical and large-animal studies
Connect quality to the study: consider particle content, genome integrity, impurities, handling stability, and relevant activity. Host immunity is a study-context question rather than a universal lot-release attribute.
Decision supported: full/empty capsid analysis and freeze-thaw stability.
GMP and clinical-grade lots
Full release testing: identity, titer, purity, genome integrity, and comprehensive safety testing under a qualified method set.
Decision supported: viral vector safety and safety control considerations.
Include Handling History in the QC Plan
Record formulation, concentration, container, storage duration, and freeze–thaw history. Unchanged genome concentration alone does not rule out changes in particle integrity or activity.
Freeze–thaw-associated genome leakage has been demonstrated experimentally; the effect and mitigation are product- and formulation-dependent.[4] Evaluate representative handling conditions with matched sampling and appropriate integrity and functional endpoints, rather than applying an unsupported universal cycle limit.
Biological safety and immunogenicity also extend beyond a lot-release assay panel. Dose, route, model, and immune context remain separate considerations. Discuss viral vector safety assessment with the intended experimental use clearly specified.
From QC to Release
Creative Biolabs Support
Creative Biolabs offers a complete AAV analytical and QC service portfolio, from titration and purity to safety and characterization.
02 / PURITY
Purity detection and analysis
Discuss the protein profile and residual impurity questions that the project needs to address. Confirm whether specialized capsid-content or genome-integrity analysis is included in the agreed scope.
03 / SAFETY
Safety testing
Define the safety questions, intended use, and sample requirements. Confirm available assays and their detection limits; a negative result does not establish universal product safety.
04 / ANALYSIS
Viral vector analysis
Discuss identity, purity, and relevant activity with the intended use specified. Define the analytical deliverables and reporting limits before interpreting the lot as suitable for a study.
Selected Reading
Scientific context for AAV quality control
Genome Quantification
Lock M, Alvira MR, Chen SJ, Wilson JM. Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR. Human Gene Therapy Methods. 2014;25(2):115-125. https://doi.org/10.1089/hgtb.2013.131.
Particle Heterogeneity
Burnham B, et al. Analytical ultracentrifugation as an approach to characterize recombinant adeno-associated viral vectors. Human Gene Therapy Methods. 2015;26(6):228-242. https://doi.org/10.1089/hgtb.2015.048.
Orthogonal Analysis
Richter K, et al. Purity and DNA content of AAV capsids assessed by analytical ultracentrifugation and orthogonal biophysical techniques. European Journal of Pharmaceutics and Biopharmaceutics. 2023;189:68-83. https://doi.org/10.1016/j.ejpb.2023.05.011.
Handling Stability
Xu Y, Jiang B, Samai P, Tank SM, Shameem M, Liu D. Genome DNA leakage of Adeno-Associated virus under freeze-thaw stress. International Journal of Pharmaceutics. 2022;615:121464. https://doi.org/10.1016/j.ijpharm.2022.121464.
FAQ
AAV quality control questions
A genome assay measures a selected DNA target under the assay conditions. It does not establish capsid occupancy, a complete intended genome, or relevant biological activity.
Start Your Project Today
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
